Form 8-K - Current report:
SEC Accession No. 0000950170-24-119270
Filing Date
2024-10-31
Accepted
2024-10-31 09:15:08
Documents
12
Period of Report
2024-10-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inkt-20241030.htm   iXBRL 8-K 38938
2 EX-99.2 inkt-ex99_2.htm EX-99.2 9943
  Complete submission text file 0000950170-24-119270.txt   170131

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20241030.xsd EX-101.SCH 25843
14 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20241030_htm.xml XML 4885
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 241412714
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)